Efficacy and Safety of Rifasutenizol (TNP 2198) in Participants With H. Pylori Infection

Sponsor

TenNor Therapeutics (Suzhou) Limited (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05857163

Collaborator

(none)

700

Enrollment

Location

Arms

17.1

Anticipated Duration (Months)

41.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A multi-center, randomized, double-blind, bismuth-containing quadruple active comparator-controlled Phase 3 clinical study to evaluate the efficacy and safety of Rifasutenizol in combination with rabeprazole and amoxicillin in the primary treatment of participants with H. pylori infection using an adaptive design with sample size re-estimation.

Subjects will be randomly assigned to test group or control group at a 1:1 ratio stratified by study site, and will receive Rifasutenizol capsules, rabeprazole sodium enteric-coated tablets, amoxicillin capsules combined with clarithromycin placebo tablets and bismuth potassium citrate placebo capsules (test group), or bismuth-containing quadruple regimen of amoxicillin capsules, clarithromycin tablets, rabeprazole sodium enteric-coated tablets and bismuth potassium citrate capsules combined with RSZ placebo capsules (control group) for 14 consecutive days.

13C UBT will be performed 4 6 weeks after the last dose to evaluate the eradication effect of

pylori.

Condition or Disease	Intervention/Treatment	Phase
H.Pylori Infection	Drug: Rifasutenizol capsules Drug: Rabeprazole sodium enteric-coated tablets Drug: Amoxicillin Capsules Drug: Clarithromycin placebo tablets Drug: Bismuth potassium citrate placebo capsules Drug: Clarithromycin tablets Drug: Bismuth potassium citrate capsules Drug: Rifasutenizol placebo capsules	Phase 3

Study Design

Study Type:

Interventional

Anticipated Enrollment :

700 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Rifasutenizol (TNP 2198) in Combination With Rabeprazole and Amoxicillin in the Primary Treatment of Participants With H. Pylori Infection

Anticipated Study Start Date :

May 30, 2023

Anticipated Primary Completion Date :

May 30, 2024

Anticipated Study Completion Date :

Oct 30, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Test Group Rifasutenizol capsules, 400 mg, BID, taken orally within half an hour after breakfast and dinner Rabeprazole sodium enteric-coated tablets, 20 mg, BID, taken orally within half an hour before breakfast and dinner Amoxicillin capsules, 1 g, BID, taken orally within half an hour after breakfast and dinner Clarithromycin placebo tablets, BID, taken orally within half an hour after breakfast and dinner Bismuth potassium citrate placebo capsules, BID, taken orally within half an hour before breakfast and dinner	Drug: Rifasutenizol capsules 400 mg, BID Other Names: TNP-2198 capsules Drug: Rabeprazole sodium enteric-coated tablets 20 mg, BID Drug: Amoxicillin Capsules 1 g, BID Drug: Clarithromycin placebo tablets BID Drug: Bismuth potassium citrate placebo capsules BID
Active Comparator: Control Group Amoxicillin capsules, 1 g, BID, taken orally within half an hour after breakfast and dinner Clarithromycin tablets, 500 mg, BID, taken orally within half an hour after breakfast and dinner Rabeprazole sodium enteric-coated tablets, 20 mg, BID, taken orally within half an hour before breakfast and dinner Bismuth potassium citrate capsules, 240 mg, BID, taken orally within half an hour before breakfast and dinner Rifasutenizol placebo capsules, BID, taken orally within half an hour after breakfast and dinner	Drug: Rabeprazole sodium enteric-coated tablets 20 mg, BID Drug: Amoxicillin Capsules 1 g, BID Drug: Clarithromycin tablets 500 mg, BID Drug: Bismuth potassium citrate capsules 240 mg, BID Drug: Rifasutenizol placebo capsules BID

Arm

Intervention/Treatment

Experimental: Test Group

Rifasutenizol capsules, 400 mg, BID, taken orally within half an hour after breakfast and dinner Rabeprazole sodium enteric-coated tablets, 20 mg, BID, taken orally within half an hour before breakfast and dinner Amoxicillin capsules, 1 g, BID, taken orally within half an hour after breakfast and dinner Clarithromycin placebo tablets, BID, taken orally within half an hour after breakfast and dinner Bismuth potassium citrate placebo capsules, BID, taken orally within half an hour before breakfast and dinner

Drug: Rifasutenizol capsules

400 mg, BID

Other Names:

TNP-2198 capsules

Drug: Rabeprazole sodium enteric-coated tablets

20 mg, BID

Drug: Amoxicillin Capsules

1 g, BID

Drug: Clarithromycin placebo tablets

BID

Drug: Bismuth potassium citrate placebo capsules

BID

Active Comparator: Control Group

Amoxicillin capsules, 1 g, BID, taken orally within half an hour after breakfast and dinner Clarithromycin tablets, 500 mg, BID, taken orally within half an hour after breakfast and dinner Rabeprazole sodium enteric-coated tablets, 20 mg, BID, taken orally within half an hour before breakfast and dinner Bismuth potassium citrate capsules, 240 mg, BID, taken orally within half an hour before breakfast and dinner Rifasutenizol placebo capsules, BID, taken orally within half an hour after breakfast and dinner

Drug: Rabeprazole sodium enteric-coated tablets

20 mg, BID

Drug: Amoxicillin Capsules

1 g, BID

Drug: Clarithromycin tablets

500 mg, BID

Drug: Bismuth potassium citrate capsules

240 mg, BID

Drug: Rifasutenizol placebo capsules

BID

Outcome Measures

Primary Outcome Measures

Eradication rate of H.pylori Strain [4 to 6 weeks after the last dose of the study drugs]
The eradication rate of H. pylori (based on the test results of 13C UBT)

Secondary Outcome Measures

Eradication rate of Clarithromycin-resistant Strain of H.pylori [4 to 6 weeks after the last dose of the study drugs]
Percentage of Participants with Successful Helicobacter Pylori (H.pylori) Eradication in Participants with a Clarithromycin-resistant Strain of H.pylori at Baseline (based on the test results of 13C UBT)

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Voluntarily sign the informed consent form.
Age 18-65 years (inclusive), male or female.
The result of 13C-UBT is positive (≥ 4 Delta Over Baseline), and the infection of H. pylori are confirmed by gastroscopic biopsy histology.
Subjects agree to refrain from taking any antibiotics or traditional Chinese medicines with antibacterial effect, bismuth, and antacids (such as PPI, H2 receptor blocker, P-CAB) other than the study drugs during the Screening Period until the end of the study (Visit 5, i.e., Efficacy Evaluation Visit).
Subjects and their heterosexual partners must agree to have no pregnancy plan and voluntarily take effective contraceptive measures during the trial and for at least 6 months after the end of the study medication.
Willing to follow and able to complete all trial procedures.

Exclusion Criteria:

Allergy to any of the study drugs (rabeprazole, amoxicillin, clarithromycin, bismuth potassium citrate), allergic constitution (multiple drug and food allergies); or any contraindication to the use of rifamycin, nitroimidazoles or study drugs.
History of H. pylori eradication therapy (including participation in other clinical trials for H. pylori eradication).
Subjects with confirmed tuberculosis (TB) or Mycobacterium avium complex (MAC) infection or a history of TB or MAC infection.
History of dysphagia or any gastrointestinal disorder affecting drug absorption.
History of obstruction pyloric; or excessive gastric acid secretion (such as Zollinger-Ellison syndrome).
History of gastric cancer.
History of neoplasm malignant within 5 years prior to screening, with the exception of basal cell carcinoma or carcinoma cervix in situ treated without evidence of recurrence.
History of esophageal or gastric surgery, except for simple repair of the perforated ulcer.
History of substance abuse or drug use within 5 years prior to screening.
Alcohol abuse or a history of alcohol abuse within 5 years prior to screening (average weekly consumption of ≥ 14 units of alcohol: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine/Chinese rice wine/rice wine);
Presence of active gastric and/or duodenal ulcer.
Anticoagulant therapy or long-term treatment with nonsteroidal anti-inflammatory drugs.
Treatment with any other investigational new drugs within 4 weeks prior to the Screening Period.
Any prohibited medications or non-drug therapies as specified in the protocol (see Section 10.3).
White blood cell count or neutrophil count below the lower limit of normal range.
Anemia (hemoglobin < 90 g/L).
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, or serum creatinine above the upper limit of normal range.
Test positive for hepatitis B surface antigen, hepatitis C antibody, AIDS antibody, or microspironema pallidum antibody.
Abnormal ECG with clinical significance.
Female subjects who are pregnant, lactating, or have a positive urine pregnancy result during the Screening Period.
Inability to communicate with the Investigator and to comply with the study requirements.
Other conditions considered inappropriate to participate in this study by the Investigator, e.g., the subject has a history of severe central nervous system, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, endocrine, or hematological diseases, or has clinical manifestations of these diseases.